drugset / Trial / NCT07380633
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
Toripalimab and bevacizumab (T-B) was approve for unresectable hepatocellular carcinoma (uHCC). Transartial therapies, including transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), and TACE-HAIC are commonly used for uHCC. Increasing evidence showed that combined systemic therapy and transarterial therapy will improve the response rate for those patients. It is unknown whether which tranarterial therapy will proved favorable efficiency when combined T-B. This phase 2 clinical trial aims to investigate the short outcome of T-B with three distinct transarterial therapies for uHCC.
Timeline
- Start
- 2026-01-23
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Epirubicin | Small molecule | 30 mg/m2 | Other |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Comparator | carb | Unknown | 300 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Other |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | — |
| Comparator | lipiodol | Unknown | — | Other |